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To the Editor:
We read with great interest the article 
by Um et al.,1 reporting on a prospec-
tive trial in a tertiary referral center to 
compare the diagnostic performance of 
endobronchial ultrasound-guided trans-
bronchial needle aspiration (EBUS-
TBNA) with that of mediastinoscopy 
for nodal staging of patients with 
non–small-cell lung cancer (NSCLC).
Treatment and prognosis in lung 
cancer is critically dependent on stage. In 
the absence of distant metastases, medi-
astinal staging becomes vital for the cor-
rect management of NSCLC. By the way, 
according to recent American College of 
Chest Physicians and European Society 
of Thoracic Surgeons guidelines, mini-
mally invasive endoscopic techniques 
are the first choice if local expertise with 
EBUS/endoscopic ultrasound (EUS) 
needle aspiration is available.2,3
Although mediastinoscopy is con-
sidered the diagnostic standard, several 
meta-analyzes2,4 stated the diagnostic 
sensitivities of EBUS-TBNA range from 
88% to 93%, comparable to those of 
traditional mediastinoscopy (78%) and 
video-assisted mediastinoscopy (89%).
In this setting, the abovementioned 
study strongly supports the diagnostic 
performance of EBUS-TBNA in medias-
tinal staging of cN1–N3 with a sensitiv-
ity and negative predictive value (NPV) 
of 88% and 85.2%, respectively, versus 
81.3% and 78.8% of mediastinoscopy.
Accordingly, we wish to submit 
our reflections to foster brainstorming 
on the strategy for proper work up in 
mediastinal staging of NSCLC.
Recently, Evison et al.5 proposed 
and validated a risk stratification model 
for lymph nodes classified as negative 
by EBUS-TBNA. This model combined 
positron emission  tomography (PET)-
computed tomography and EBUS data 
to stratify patients into high and low risk 
for nodal malignancy. According to the 
authors, this model could aid lung cancer 
multidisciplinary teams in deciding which 
patients need further staging procedures 
after a negative EBUS and which not.
But staging pathway is heavily 
marked by local expertise and profi-
ciency of EBUS operators.
So, while in referral center for 
NSCLC, EBUS-TBNA should be the 
first-choice procedure performed in 
nodal staging and more invasive medi-
astinoscopy should be reserved to fewer 
patients (those with a negative TBNA but 
high suspicion of malignancy according 
to PET-computed tomography/EBUS 
data—high-risk patients in Evison’s 
model—and multidisciplinary team 
decision), in case of less-experienced 
groups the sensitivity of EBUS could 
be lower. Therefore, mediastinoscopy is 
still recommended in this contest.
Are we at the dusk of mediasti-
noscopy in staging of cN1–N3 NSCLC 
in modern clinical practice in experi-
enced center?
Or is mediastinsocopy still a diag-
nostic standard above all in cN0?
By the way, though recent guide-
lines also recommended nodal sampling 
in case of centrally located tumor with 
PET-negative nodes or in case of 5 mm 
nodes, the diagnostic performance of 
EBUS-TBNA is not yet proven in these. 
So mediastinoscopy could be an impor-
tant validation tool of EBUS-TBNA 
results.
On the basis of the data reported, 
we would really appreciate the authors’ 
reflections and reaction on the impact 
of EBUS-TBNA in NSCLC staging and 
the role of mediastinoscopy on modern 
clinical practice.
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In Response:
At 2010, the lung cancer team of 
Samsung Medical Center agreed to 
begin the prospective study to directly 
compare the endobronchial ultrasound-
guided transbronchial needle aspiration 
(EBUS-TBNA) with mediastinoscopy 
LETTERS TO THE EDITOR
